OctoPlus announces publication of key Phase IIb results for Locteron

01-Nov-2010 - Netherlands

OctoPlus N.V. announces that its licensee Biolex Therapeutics has published positive interim results at week 60 of the Phase IIb trial, 12 weeks after completion of 48 weeks of treatment with Locteron®. The results are consistent with the existing clinical results for Locteron and confirm Locteron's improved tolerability profile.

Simon Sturge, CEO of OctoPlus, says: "These positive results further demonstrate the value of our PolyActive® technology and show that Locteron's targeted benefits are sustained in the long term, up to 12 weeks after the end of treatment. Based on increasing evidence we believe that interferon alpha will remain a core component of future hepatitis C treatment regimens, and these positive results position Locteron as a key product in hepatitis C therapy."

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

Last viewed contents